Clinical Trial

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Study acronym: KaiNETIC-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Protocol Amendment History 9 changes
critical Primary endpoint(s) modified 2026-07-16
notable Enrollment reduced: 1700 -> 1156 participants 2026-07-16
notable Trial sites expanded: 58 -> 116 locations 2026-07-16
notable Trial sites expanded: 52 -> 58 locations 2026-06-19
notable Trial sites expanded: 49 -> 52 locations 2026-06-09
notable Trial sites expanded: 37 -> 44 locations 2026-05-09
notable Trial sites expanded: 30 -> 36 locations 2026-04-29
notable Trial sites expanded: 27 -> 30 locations 2026-04-10
notable Trial sites expanded: 24 -> 27 locations 2026-04-01
Trial Details
NCT Number NCT07284901
Lead Sponsor Kailera
Conditions Obesity With Diabetes, Overweight With Diabetes
Enrollment 1,156 participants
Start Date 2026-01-12
Primary Completion 2028-03-27 (estimated)
Study Completion 2028-04-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-15